Indoor environments are major contributing locations where the respiratory virus transmission occurs. Higher air change rate (ACH) values (up to 12) have been recommended in hospital environments to reduce virus transmission. In the present study, the Large Eddy Simulation (LES) data of particle transport in a typical intensive care unit (ICU) is used to calculate the infection risk in close proximity interaction. Three different ACH (6, 9, 12) rates with face masks and one case with a healthy person wearing a face shield are considered. The average resident time of the droplets in the ICU is calculated to find the optimal ACH rate. Of the different types of masks analyzed in the present study, the triple-layer mask has shown the most resistance ([Formula: see text] probability of infection) to the penetration of virus-laden droplets, while the single-layer mask has shown the highest risk of infection (up to [Formula: see text]. The results show that the ACH rate has little effect on close proximity transmission. The ACH 9 case provided optimal value for the particle removal, while the ACH 12 has inferior performance to that of ACH 9. From an energy consumption view, our results recommend not using higher ACH in similar indoor environments. Inside indoor environments, it is advised to wear a three-layer face mask and face shield to reduce the risk of infection.

31 Mar 2020·Preventive Nutrition and Food Science

Vitis vinifera L. Grape Skin Extract Prevents Development of Hypertension and Altered Lipid Profile in Spontaneously Hypertensive Rats: Role of Oxidative Stress

Article

Author: Ognibene, Dayane Teixeira ; da Costa, Giselle França ; Moura, Aníbal Sanchez ; Resende, Angela de Castro ; de Bem, Graziele Freitas ; Cordeiro, Viviane da Silva Cristino ; Teixeira, Michelle Teixeira ; da Costa, Cristiane Aguiar ; de Moura, Roberto Soares

This study investigated the protective effect of a Vitis vinifera L. grape skin extract (ACH09) on blood pressure, lipid profile, and oxidative status in spontaneously hypertensive rats (SHR). Systolic blood pressure (SBP), total cholesterol, triglyceride, and glucose levels, as well as oxidative damage and antioxidant activity in the plasma and kidney, were evaluated in four experimental groups: control Wistar rats (W-C) and SHR-C that received water, and Wistar rats and SHR treated with ACH09 (200 mg/kg/d) in drinking water for 12 weeks (W-ACH09 and SHR-ACH09, respectively). SBP increased in the SHR group compared with the W groups and the treatment with ACH09 prevented the development of hypertension. Plasma triglyceride and total cholesterol levels increased in SHR compared with W-C rats; these changes prevented by treatment with ACH09. Glucose levels did not differ between the groups. The SHR group had increased oxidative damage in plasma, as expressed by 2-thiobarbituric acid reactive substances (TBARS) levels, and this prevented by ACH09. Levels of TBARS in the kidneys were lower in the SHR-ACH09 group than in the SHR-C group. Further, ACH09 increased the superoxide dismutase activity in both the plasma and kidneys of both SHR and Wistar rats. These results suggest that ACH09 is protective against disruption of blood pressures, oxidant status, and lipid profile in SHR, and provide important evidence on the benefits of ACH09 on hypertension and associated cardiovascular complications.

01 Jul 2017·Nutrition ResearchQ4 · MEDICINE

Supplementation with Vitis vinifera L. skin extract improves insulin resistance and prevents hepatic lipid accumulation and steatosis in high-fat diet–fed mice

Q4 · MEDICINE

Article

Author: Angela Castro Resende ; Viviane Silva Cristino Cordeiro ; Ana Paula Machado da Rocha ; Graziele Freitas de Bem ; Roberto Soares de Moura ; Dayane Teixeira Ognibene ; Izabelle Barcellos Santos ; Gisele França da Costa ; Lenize Costa Reis Marins de Carvalho ; Cristiane Aguiar da Costa

Nonalcoholic fatty liver disease is one of the most common complications of obesity. The Vitis vinifera L. grape skin extract (ACH09) is an important source of polyphenols, which are related to its antioxidant and antihyperglycemic activities. We hypothesized that ACH09 could also exert beneficial effects on metabolic disorders associated with obesity and evaluated ACH09's influence on high-fat (HF) diet-induced hepatic steatosis and insulin resistance in C57BL/6 mice. The animals were fed a standard diet (10% fat, control) or an HF diet (60% fat, HF) with or without ACH09 (200mg/[kg d]) for 12weeks. Our results showed that ACH09 reduced HF diet-induced body weight gain, prevented hepatic lipid accumulation and steatosis, and improved hyperglycemia and insulin resistance. The underlying mechanisms of these beneficial effects of ACH09 may involve the activation of hepatic insulin-signaling pathway because the expression of phosphorylated insulin receptor substrate-1, phosphatidylinositol 3-kinase, phosphorylated Akt serine/threonine kinase 1, and glucose transporter 2 was increased by ACH09 and correlated with improvement of hyperglycemia, hyperinsulinemia, and insulin resistance. ACH09 reduced the expression of the lipogenic factor sterol regulatory-element binding protein-1c in the liver and upregulated the lipolytic pathway (phosphorylated liver kinase B1/phosphorylated adenosine-monophosphate-activated protein kinase), which was associated with normal hepatic levels of triglyceride and cholesterol and prevention of steatosis. ACH09 prevented the hepatic oxidative damage in HF diet-fed mice probably by restoration of antioxidant activity. In conclusion, ACH09 protected mice from HF diet-induced obesity, insulin resistance, and hepatic steatosis. The regulation of hepatic insulin signaling pathway, lipogenesis, and oxidative stress may contribute to ACH09's protective effect.

100 Deals associated with ACH-09

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metabolic Syndrome	Phase 3	-	Aché Laboratórios Farmacêuticos SA	-

Clinical Result

Indication

Phase

Evaluation

View All Results

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis


No Data

ACH-09

Overview

Basic Info

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation